Peter Salzmann Biography and Net Worth

CEO of Immunovant

Peter Salzmann, M.D., M.B.A, is the Chief Executive Officer of Immunovant and a member of our board of directors. From November 2018 to June 2019, he served as a Global Brand Development Leader in Immunology at Eli Lilly and Company, where he was responsible for the design of a comprehensive indication strategy and oversaw Phase 2 and 3 clinical trial execution. From March 2013 to October 2018, Dr. Salzmann was Head of U.S. Immunology at Eli Lilly, and he also served as Managing Director of Lilly Alps from January 2011 to April 2013. From January 2008 to December 2010, Dr. Salzmann was the Head of Marketing for Eli Lilly China.

Dr. Salzmann earned a B.A. in Chemistry from Northwestern University, an M.D. from University of Chicago’s Pritzker School of Medicine, and an M.B.A. from Stanford University’s Graduate School of Business.

What is Peter Salzmann's net worth?: The estimated net worth of Peter Salzmann is at least $25.51 million as of November 20th, 2024. Dr. Salzmann owns 978,097 shares of Immunovant stock worth more than $25,508,770 as of December 24th. This net worth evaluation does not reflect any other investments that Dr. Salzmann may own. Additionally, Dr. Salzmann receives an annual salary of $1,020,000.00 as CEO at Immunovant. Learn More about Peter Salzmann's net worth.
How old is Peter Salzmann?: Dr. Salzmann is currently 56 years old. There are 6 older executives and no younger executives at Immunovant. Learn More on Peter Salzmann's age.
What is Peter Salzmann's salary?: As the CEO of Immunovant, Inc., Dr. Salzmann earns $1,020,000.00 per year. Learn More on Peter Salzmann's salary.
How do I contact Peter Salzmann?: The corporate mailing address for Dr. Salzmann and other Immunovant executives is 320 WEST 37TH STREET, NEW YORK NY, 10018. Immunovant can also be reached via phone at 917-580-3099 and via email at [email protected]. Learn More on Peter Salzmann's contact information.
Has Peter Salzmann been buying or selling shares of Immunovant?: Over the course of the past ninety days, Peter Salzmann has sold $1,243,305.45 in shares of Immunovant stock. Most recently, Peter Salzmann sold 16,692 shares of the business's stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $25.45, for a transaction totalling $424,811.40. Following the completion of the sale, the chief executive officer now directly owns 978,097 shares of the company's stock, valued at $24,892,568.65. Learn More on Peter Salzmann's trading history.
Who are Immunovant's active insiders?: Immunovant's insider roster includes Peter . (), Eva Barnett (CFO), Julia Butchko (Insider), Michael Geffner (Chief Medical Officer), Douglas Hughes (Director), Mark Levine (Chief Legal Officer and Corporate Secretary), William Macias (Insider), George Migausky (Director), Atul Pande (Director), Peter Salzmann (CEO), Jay Stout (CTO), and Frank Torti (Director). Learn More on Immunovant's active insiders.
Are insiders buying or selling shares of Immunovant?: During the last twelve months, insiders at the sold shares 38 times. They sold a total of 226,233 shares worth more than $6,598,313.84. The most recent insider tranaction occured on November, 20th when insider Mark S Levine sold 3,650 shares worth more than $92,892.50. Insiders at Immunovant own 5.9% of the company. Learn More about insider trades at Immunovant.
Information on this page was last updated on 11/20/2024.

Peter Salzmann Insider Trading History at Immunovant

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/20/2024	Sell	16,692	$25.45	$424,811.40	978,097
11/20/2024	Sell	16,692	$25.45	$424,811.40	978,097
10/16/2024	Sell	9,095	$28.79	$261,845.05	994,789
10/9/2024	Sell	4,460	$29.56	$131,837.60	1,003,884
7/17/2024	Sell	8,685	$29.69	$257,857.65	1,023,412
7/9/2024	Sell	4,619	$28.06	$129,609.14	1,032,097
5/22/2024	Sell	16,163	$29.65	$479,232.95	1,036,716
4/17/2024	Sell	34,079	$29.06	$990,335.74	1,052,879
4/9/2024	Sell	4,807	$31.18	$149,882.26	1,086,958
1/5/2024	Sell	3,824	$38.59	$147,568.16	944,685
11/22/2023	Sell	16,217	$32.78	$531,593.26	948,509
10/5/2023	Sell	5,239	$36.24	$189,861.36	964,726
8/30/2023	Sell	56,774	$22.02	$1,250,163.48	969,965
8/14/2023	Sell	103,058	$21.42	$2,207,502.36	1,026,739
8/7/2023	Sell	101,339	$21.73	$2,202,096.47	1,129,797
7/12/2023	Sell	3,233	$19.73	$63,787.09	1,231,136
4/18/2023	Sell	3,395	$15.27	$51,841.65	1,234,369
1/11/2023	Sell	4,021	$16.80	$67,552.80	993,932
10/13/2022	Sell	2,793	$9.18	$25,639.74	997,953
9/28/2022	Sell	1,605	$4.67	$7,495.35	1,000,746
8/30/2022	Sell	1,644	$5.83	$9,584.52	1,002,351
7/27/2022	Sell	1,528	$4.27	$6,524.56	552,731
6/29/2022	Sell	1,376	$4.02	$5,531.52	554,259
5/24/2022	Sell	1,471	$3.79	$5,575.09	555,635
4/27/2022	Sell	1,622	$4.72	$7,655.84	557,106
3/24/2022	Sell	19,227	$5.90	$113,439.30	558,728

Peter Salzmann Buying and Selling Activity at Immunovant

Immunovant Company Overview

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Today's Range

Now: $26.08

$25.44

$26.24

50 Day Range

MA: $28.45

$25.22

$31.42

2 Week Range

Now: $26.08

$24.61

$45.58

Volume

908,488 shs

Average Volume

1,068,167 shs

Market Capitalization

$3.83 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.64

After New Years, price goes back up 4,800%

From StocksToTrade | Ad

When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds for a dollar anymore!

Click here to review Tim’s special Holiday offer before it’s too late.

Peter Salzmann Biography and Net Worth

What is Peter Salzmann's net worth?

How old is Peter Salzmann?

What is Peter Salzmann's salary?

How do I contact Peter Salzmann?

Has Peter Salzmann been buying or selling shares of Immunovant?

Who are Immunovant's active insiders?

Are insiders buying or selling shares of Immunovant?